Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

FDA headquarters at White Oak Campus in Silver Spring, Maryland, USA - January 13, 2020. The United States Food and Drug Administration (FDA) is a federal agency. | Image credit: © JHVEPhoto - © JHVEPhoto - stock.adobe.com

September 23rd, 2026

FDA Formalizes Non-Animal Testing Methods in New Rule

FDA's new rule formally recognizes non-animal methods like organoids and AI models as valid ways to support human drug testing.

In Modern Laboratory Senior Female Scientist Has Discussion with Young Male Laboratory Assistant. He Shows Her Data Charts on a Clipboard, She Analyzes it and Enters It into Her Computer. | Image credit: © Gorodenkoff - © Gorodenkoff - stock.adobe.com

September 21st, 2026

How Risk-Based Monitoring Redistributes and Reshapes Capacity Planning

New data show risk-based and centralized monitoring shifts effort across roles, sites, and timelines, reshaping how sponsors plan CRA capacity needs.

FDA drug approval process, pharmaceutical regulatory compliance, food and drug administration certification, medical product approval concept, drug testing and approval | image credit: © Сергей Шиманович - © Сергей Шиманович - stock.adobe.com

September 17th, 2026

CBER, CDER Compliance Leaders Outline 2026 Guidance Shifts and Rising GMP Violations

FDA compliance officers detailed 2026 guidance updates, online drug sale enforcement, and a first-of-its-kind AI-related warning letter at the PDA/FDA Joint Regulatory Conference.

Global shipping and supply chain vector illustration. Abstract concept with world map background and connected icons related to international import / export, distribution and transportation. | Image credit: © j-mel - © j-mel - stock.adobe.com

September 17th, 2026

FDA, Genentech, Minaris Panelists Detail Raw Material Risk Strategies for Advanced Therapies

Panelists from FDA, Genentech, and Minaris discussed raw material risk, supplier oversight, and at-risk release strategies for advanced therapies at the PDA/FDA Joint Regulatory Conference.

September 16th, 2026

CDER, CBER Officials Outline GMP Compliance Trends

FDA's Francis R.W. Godwin (CDER) and Kathleen Jones, PhD (CBER) detail a record pace of drug warning letters and the CGMP deficiencies most commonly cited in biologics facility inspections.

Global health safety regulation Concept, Businesswoman reviewing and approving FDA standard documents for medical and food, Compliance, laboratory inspection, certification, and international approval | Image credit: © Ticha - © Ticha - stock.adobe.com

September 16th, 2026

FDA, Sanofi, Gilead Weigh AI Readiness and Validation Risk at PDA/FDA Conference

Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.

Team of Research Scientists in Sterile Suits Working with Computers, Microscopes and Modern Industrial Machinery in the Laboratory. Product Manufacturing Process: Pharmaceutics, Biotechnology. | Image credit: © Gorodenkoff - © Gorodenkoff - stock.adobe.com

September 16th, 2026

FDA Highlights Aseptic Processing Pitfalls at PDA/FDA Conference

FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.

3D X-ray-style illustration of a human torso with the kidneys, ureters, bladder, and urethra highlighted in orange against a blue background. | Image Credit: © Matthieu - stock.adobe.com

September 25th, 2026

FDA Grants Priority Review to Perioperative Imfinzi Plus Enfortumab Vedotin in Cisplatin-Ineligible Bladder Cancer

AstraZeneca's sBLA for durvalumab combined with neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer, based on the Phase 3 VOLGA trial, has a PDUFA date expected in the fourth quarter of 2026.